-

11:04:39 AM

MRNA Stock News

MRNA - Moderna Inc

01/10/22 7:00 AM

Nasdaq : MRNA

Moderna Announces Advances Across Its Industry-Leading mRNA Pipeline and Provides Business Update

807 million doses of Moderna's COVID-19 vaccine shipped globally in 2021; approximately 25% of those doses shipped to low- and middle-income countries Product sales for 2021 approximately $17.5 billion (unaudited) Increasing APAs for 2022 delivery to approximately $18.5 billion and approximately

RHEA-AI

neutral

01/10/22 6:30 AM

Nasdaq : MRNA

Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology

Moderna Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Carisma Therapeutics Inc., a biopharmaceutical pioneer in engineered macrophage-based therapeutics, today announced

RHEA-AI

very positive

01/05/22 7:00 AM

Nasdaq : MRNA

clinical trial

Moderna Announces First Participant Dosed in Phase 1 Study of its mRNA Epstein-Barr Virus (EBV) Vaccine

Moderna expects to enroll approximately 270 participants in the U.S. EBV is a major cause of infectious mononucleosis, which can debilitate patients for weeks to months; there is no approved vaccine to prevent EBV EBV can also lead to lifelong medical conditions and is associated with an increased

RHEA-AI

negative

01/04/22 4:01 PM

Nasdaq : MRNA

conferences

Moderna to Present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will participate in a fireside chat at the Goldman Sachs 14 th Annual Healthcare CEOs Unscripted

RHEA-AI

neutral

01/03/22 10:30 AM

Nasdaq : MRNA

Moderna to Provide Business and Pipeline Updates at the 2022 J.P. Morgan Healthcare Conference

Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at the virtual

RHEA-AI

neutral

12/27/21 5:00 PM

Nasdaq : MRNA

covid-19

Moderna Announces Supply Agreement with South Korea for Additional 20 Million Doses of Moderna’s COVID-19 Vaccine or Updated Booster Candidate in 2022

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and

RHEA-AI

neutral

12/27/21 9:20 AM

Nasdaq : MRNA

covid-19

Moderna Announces Switzerland Exercises its Option to Purchase Seven Million Additional Doses of Moderna's COVID-19 Booster Vaccine in 2022

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Swiss Federal Government has

RHEA-AI

very positive

12/20/21 5:00 AM

Nasdaq : MRNA

Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, today announced preliminary neutralizing antibody data against the Omicron variant following the Company’ s booster candidates at 50 µg and 100 µg dose levels. However, these data showing that the currently authorized Moderna COVID-19 booster can boost...

RHEA-AI

neutral

12/13/21 6:00 PM

Nasdaq : MRNA

Moderna and Australia Announce Collaboration to Bring mRNA Manufacturing to Australia

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, today announced an agreement in principle with the Australian Government to build a state-of-the-art messenger RNA vaccine manufacturing facility in Victoria, Australia including access to Moderna’ s mRNA development engine.

RHEA-AI

positive

12/10/21 9:00 AM

Nasdaq : MRNA

covid-19

Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, today announced an amendment to its existing contract with Gavi, the Vaccine Alliance, to accelerate supply of 20 million doses to COVAX by December 31, 2021 for a total of 54 million doses made available to COVAX in 2021. Given the acceleration into 2021, Moderna...

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next